Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murlentamab +/- Trifluridine/Tipiracil in Advanced Colorectal Cancer
NCT03799731Phase 2Completed
- Sponsor
- GamaMabs Pharma
- Start
- Jul 2018
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of GM-102 in colorectal cancer (CRC), sponsored by GamaMabs Pharma. Started Jul 2018; status: completed.
02
Drugs
GM-102
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03799731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799731.